Health Canada's ADHD Medication Safety Review: What the Weight-Loss Signal in Children Under 6 Means for Your Labelling

Attention deficit hyperactivity disorder medicines are among the most closely watched drugs in Canada, and for good reason. They are stimulants, they are used in children, and the balance of benefit and risk depends on careful dosing and monitoring. In September 2026, Health Canada added a new line to that risk picture. Its latest safety review found a possible increased risk of weight loss in children under six years of age who receive these medicines, and it signalled that the Canadian product monographs for the whole class will be updated.

For market authorization holders, this is not an abstract safety note. It is a concrete, near-term labelling project that will touch every central nervous system stimulant indicated for ADHD. This article explains what Health Canada found, why the under-six signal matters, and exactly what updating a product monograph for a safety signal involves, from the science to the submission to the pharmacovigilance obligations that continue long after approval. It is written for the pharmaceutical regulatory and quality teams who will do the work.

Executive summary

Health Canada's September 2026 Health Product InfoWatch reported a class-wide safety review of CNS stimulants used for ADHD. Here is what matters for regulatory and quality teams.

• The review assessed a possible increased risk of weight loss in children under six years of age, compared with older children receiving equivalent doses.
• It covered the full class: amphetamine, dextroamphetamine sulfate, lisdexamfetamine dimesylate, mixed salts amphetamine and methylphenidate hydrochloride.
• Health Canada said it will work with manufacturers to update the safety information in the Canadian product monograph for all CNS stimulants for ADHD.
• These products are generally authorized for patients six years and older, so use in younger children is off-label, which shapes how the risk should be communicated.
• Every affected market authorization holder should expect a product monograph safety update and should prepare its labelling, pharmacovigilance and change-control processes now.

What Health Canada found

In short: Health Canada's September 2026 safety review concluded there may be an increased risk of weight loss in children under six years of age treated with CNS stimulants for ADHD, compared with older children at equivalent doses, and it will update the product monographs for the entire class.

The finding was published in the September 2026 Health Product InfoWatch and in a dedicated Summary Safety Review. Health Canada assesses potential safety issues by reviewing Canadian and international adverse reaction reports, published literature and information from manufacturers. In this case the concern was a differential effect: younger children appeared more susceptible to weight loss than older children given comparable doses. Weight loss and appetite suppression are known effects of stimulants, but a stronger effect in very young children carries added significance because growth in early childhood is so important.

Health Canada's stated action, set out in the Summary Safety Review, is to work with manufacturers to update the safety information in the Canadian product monograph for all CNS stimulants for ADHD. That means the change is class-wide, not limited to a single brand or molecule.

Why the under-six signal matters

In short: CNS stimulants for ADHD are generally authorized in Canada for patients six years and older. Use in children under six is off-label, and the review suggests those youngest patients may be more vulnerable to weight loss, so the labelling must help prescribers weigh that risk.

When a drug is used outside its authorized age range, the manufacturer still carries safety-monitoring responsibilities, and Health Canada still acts on signals. A product monograph that clearly states what is known about risk in younger children helps prescribers who are considering off-label use make an informed decision, and helps caregivers understand what to watch for. Growth monitoring, including height and weight tracking, is a standard part of paediatric stimulant care, and a strengthened warning reinforces it. This is also a reminder that paediatric safety is a running theme in Canadian drug regulation, connected to initiatives like the 180-day pediatric drug review.

What a product monograph safety update involves

In short: updating a product monograph for a safety signal means revising the relevant sections, such as Warnings and Precautions, Adverse Reactions and the patient medication information, submitting the change to Health Canada through the correct regulatory pathway, and implementing it under change control with version tracking.

A product monograph is the authoritative, factual, scientific document that describes a drug and the conditions of its safe and effective use. When a safety signal requires a labelling change, the affected sections typically include Warnings and Precautions, Adverse Reactions, Dosage and Administration where relevant, and the plain-language Patient Medication Information. For a class-wide action, Health Canada often coordinates consistent wording across products so prescribers see the same message regardless of brand.

The mechanics matter. Safety-related labelling changes are submitted to Health Canada, tracked under your change-control system, and reflected in printed and electronic materials, distributor communications and, where applicable, healthcare professional letters. Missing a section, using inconsistent wording, or failing to version-control the update are common findings that turn a routine change into a compliance problem. Disciplined labelling controls that prevent errors are what keep a class-wide update clean.

The regulatory backdrop: labelling authority and Vanessa's Law

In short: Health Canada can require safety labelling changes. Under the Food and Drugs Act, as strengthened by Vanessa's Law, the Minister has the authority to order a label or product monograph change when a therapeutic product presents a serious risk of injury to health, and manufacturers must comply.

Most safety labelling updates happen cooperatively, with the manufacturer and Health Canada agreeing on wording. But the backstop is statutory. Vanessa's Law, the Protecting Canadians from Unsafe Drugs Act, gave Health Canada stronger post-market powers, including the ability to order label changes and recalls and to require the assessment of a product's risks. A company that treats a safety-review signal as optional is misreading the regulatory reality.

Pharmacovigilance does not end at approval

In short: a safety review is the pharmacovigilance system working. Manufacturers must continue to collect, assess and report adverse reactions, and to reflect new safety knowledge in their labelling and periodic safety reporting.

The weight-loss signal did not appear from nowhere. It came from adverse reaction reports, literature and manufacturer data reviewed through Health Canada's MedEffect and Canada Vigilance systems. Market authorization holders have ongoing obligations to monitor safety, submit expedited and periodic reports, and keep the product monograph current. Building a disciplined pharmacovigilance and summary-reporting process is what lets you respond to a signal like this in weeks rather than scrambling.

ADHD stimulant labelling and safety-review compliance checklist

If you hold a market authorization for a CNS stimulant used in ADHD, work through this list now.

• Confirm which of your products fall within the CNS stimulant ADHD class named in the review.
• Map the product monograph sections the weight-loss signal affects, especially Warnings and Precautions and Patient Medication Information.
• Prepare draft labelling language consistent with any class-wide wording Health Canada coordinates.
• Confirm the correct regulatory pathway for the safety labelling change and your timelines.
• Log the change under change control with version numbers and effective dates.
• Plan updates to printed labelling, electronic monographs, and distributor and pharmacy materials.
• Decide whether a healthcare professional communication is required and draft it.
• Review your pharmacovigilance procedures for capturing weight-loss and growth-related adverse reactions.
• Check that your periodic safety and summary reporting reflects the new signal.
• Document caregiver-facing guidance on growth monitoring in the patient information.

Common mistakes when responding to a safety review

• Assuming an off-label paediatric signal does not apply because the product is authorized only for ages six and older.
• Updating one brand or molecule and missing others in the same class you also hold.
• Changing Warnings and Precautions but forgetting the plain-language Patient Medication Information.
• Using wording inconsistent with Health Canada's coordinated class language.
• Failing to version-control the labelling change, so printed and electronic materials drift out of sync.
• Treating the safety review as a one-time edit rather than a trigger to strengthen ongoing pharmacovigilance.

Frequently asked questions

What did Health Canada's 2026 CNS stimulant safety review find?

It found a possible increased risk of weight loss in children under six years of age treated with CNS stimulants for ADHD, compared with older children receiving equivalent doses. Health Canada said it will work with manufacturers to update the Canadian product monograph for all CNS stimulants for ADHD. The finding was published in the September 2026 Health Product InfoWatch and a Summary Safety Review.

Which drugs are affected?

The review covered the class of CNS stimulants used for ADHD, including amphetamine, dextroamphetamine sulfate, lisdexamfetamine dimesylate, mixed salts amphetamine and methylphenidate hydrochloride. Because the action is class-wide, all market authorization holders for these products should expect a product monograph safety update.

Are these medicines approved for children under six?

CNS stimulants for ADHD are generally authorized in Canada for patients six years and older, so use in children under six is off-label. The safety review addresses risk in that younger group specifically, which is why clear labelling on the point matters for prescribers considering off-label use.

What does a product monograph safety update involve?

It means revising the affected monograph sections, usually Warnings and Precautions, Adverse Reactions and the Patient Medication Information, submitting the change to Health Canada through the correct pathway, implementing it under change control with version tracking, and updating printed and electronic materials. For class-wide actions, Health Canada often coordinates consistent wording across products.

Can Health Canada force a labelling change?

Yes. Under the Food and Drugs Act, strengthened by Vanessa's Law, the Minister can order a label or product monograph change when a therapeutic product presents a serious risk of injury to health. Most changes are cooperative, but the statutory authority is the backstop, so companies should treat a safety-review signal as a firm expectation.

What should manufacturers do now?

Confirm which of your products are in scope, map the affected monograph sections, prepare consistent labelling language, log the change under change control, plan communications, and review your pharmacovigilance and summary-reporting processes so you can capture and report weight-loss and growth-related adverse reactions. Acting early turns a class-wide safety update into a routine project rather than a scramble.

How MFLRC can help

MFLRC supports pharmaceutical market authorization holders through exactly this kind of class-wide safety update. Our regulatory affairs team can identify which of your products fall within the review, revise the affected product monograph sections with clear and consistent wording, and manage the labelling submission to Health Canada through the correct pathway. Our quality assurance team can strengthen the change control, version tracking and document management that keep printed and electronic labelling in sync, and review your pharmacovigilance and summary-reporting procedures so future signals are caught and reported on time. Whether you hold one ADHD stimulant or several, we help you turn a safety review into a controlled, defensible labelling project.

Do you hold a market authorization for a CNS stimulant used in ADHD? Get ahead of the product monograph update before the timeline gets tight.

Conclusion

Health Canada's September 2026 safety review is a clear, class-wide signal: the Canadian product monographs for CNS stimulants used in ADHD will change to reflect a possible increased risk of weight loss in children under six. For manufacturers, the work is predictable and manageable if it starts now. Confirm scope, revise the right sections, submit through the right pathway, control the change, and keep pharmacovigilance running. The companies that treat this as a routine, well-documented project will clear it quickly. The ones that wait will do the same work later, under more pressure.

Sources and references

• Health Canada, Health Product InfoWatch: September 2026
• Health Canada, Summary Safety Review: Central Nervous System Stimulants for ADHD, weight loss in children under 6 years
• Health Canada, Product monograph guidance documents and notices
• Health Canada, MedEffect Canada and the Canada Vigilance Program
• Government of Canada, Food and Drugs Act (R.S.C., 1985, c. F-27)